The Netherlands
AZAFAROS B.V., founded in 2018, is a biotechnology company focused on innovative treatment options for rare metabolic disorders. Harnessing the expertise of seasoned industry professionals and scientists, the company aims to revolutionize the therapeutic landscape for rare genetic conditions through a robust pipeline of oral small molecules.
At the forefront of its initiatives is the proprietary lead compound, nizubaglustat, designed to combat inherited life-threatening lysosomal storage diseases, conditions currently lacking effective treatments. This compound, grounded in research from Leiden University and Amsterdam UMC, uniquely interferes with glycolipid metabolism, impacting critical disease pathways through a dual mode of action.
Recently, AZAFAROS B.V. secured a substantial €132.00M Series B investment on 01 May 2025, highlighting strong backing from prominent investors such as BioGeneration Ventures, Forbion, Jeito Capital, Seroba Life Sciences, Schroders Capital, and Pictet. This capital infusion will bolster its clinical advancements and expand its drug discovery into other rare metabolic disorders.
